Diego Sadler MD FACC (@dsadlermd) 's Twitter Profile
Diego Sadler MD FACC

@dsadlermd

Cleveland Clinic Florida. Heart and Vascular Institute. Head Cardio Oncology Section. ACC Cardio Oncology Leadership Council. Opinions/tweets are my own.

ID: 1910002843

calendar_today27-09-2013 03:46:09

1,1K Tweet

1,1K Followers

656 Following

American College of Cardiology (@accintouch) 's Twitter Profile Photo

Day 2️⃣ highlights from ACC's #CardioOnc: ☑️ Significant reductions in cardiac dose w/ improved radiation therapy ☑️ TKI cardiomyopathy may be reversible w/ GDMT & 🔎 monitoring ☑️ Breast cancer survivors are at an ↗️ long-term CV risk ☑️ And more! #ACCCardioOnc

Day 2️⃣ highlights from ACC's #CardioOnc:
☑️ Significant reductions in cardiac dose w/ improved radiation therapy
☑️ TKI cardiomyopathy may be reversible w/ GDMT & 🔎 monitoring
☑️ Breast cancer survivors are at an ↗️ long-term CV risk
☑️ And more!

#ACCCardioOnc
JACC Journals (@jaccjournals) 's Twitter Profile Photo

In a double-blind RCT (STOP-CA), atorvastatin reduced the risk of clinically sig (≥3%) increase in diffuse myocardial fibrosis among #anthracycline-treated #lymphoma pts (8% for atorvastatin, 29% for placebo, P=0.002) at 12 months after cancer therapy initiation. #JACCCardioOnc

In a double-blind RCT (STOP-CA), atorvastatin reduced the risk of clinically sig (≥3%) increase in diffuse myocardial fibrosis among #anthracycline-treated #lymphoma pts (8% for atorvastatin, 29% for placebo, P=0.002) at 12 months after cancer therapy initiation. #JACCCardioOnc
Ana Barac, MD, PhD, FACC, FAHA (@anabaraccardio) 's Twitter Profile Photo

Congratulations Mahé Isabelle on a API-CAT practice changing #CardioOnc trial. Higher efficacy and safety of half dose apixaban in patients eith cancer and prior thromboembolic events. Subgroup analysis important for details #ACC25

Congratulations <a href="/isabellemahe1/">Mahé Isabelle</a> on a API-CAT practice changing #CardioOnc trial. Higher efficacy and safety of half dose apixaban in patients eith cancer and prior thromboembolic events. Subgroup analysis important for details  #ACC25
Mike Fradley, MD (@dr_mike_fradley) 's Twitter Profile Photo

Huge turnout for the #afib and #cardioonc session. Great pearls for managing this common issue in the setting of SCT, amyloid and BTK inhibitors #ACC25 #jacccardioonc

Huge turnout for the #afib and #cardioonc session.  

Great pearls for managing this common issue in the setting of SCT, amyloid and BTK inhibitors

#ACC25 #jacccardioonc
Ana Barac, MD, PhD, FACC, FAHA (@anabaraccardio) 's Twitter Profile Photo

What a fantastic #ACC25 meeting! All around stars for the #CardioOnc community. Some great sessions overlapped and I will be checking the content #ACCAnywhere. Here are the key points by phenomenal Dipti Gupta MD, MPH on imaging American College of Cardiology JACC Journals

What a fantastic #ACC25 meeting!  All around stars for the #CardioOnc community. Some great sessions overlapped and I will be checking the content #ACCAnywhere. Here are the key points by phenomenal <a href="/DrGuptaD/">Dipti Gupta MD, MPH</a> on imaging <a href="/ACCinTouch/">American College of Cardiology</a> <a href="/JACCJournals/">JACC Journals</a>
Oncology News Central (@oncnewscentral) 's Twitter Profile Photo

Study API-CAT: Low-dose apixaban proved noninferior to full-dose for extended #VTE prevention in active cancer—with significantly less bleeding. Practice-changing. bit.ly/3E4UxFk #ACC25 #Oncology Mahé Isabelle Diego Sadler MD FACC Simon Noble NEJM